PortfoliosLab logo
Guardant Health, Inc. (GH)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US40131M1099

CUSIP

40131M109

IPO Date

Oct 4, 2018

Highlights

Market Cap

$5.46B

EPS (TTM)

-$3.39

Total Revenue (TTM)

$774.00M

Gross Profit (TTM)

$474.77M

EBITDA (TTM)

-$397.86M

Year Range

$20.14 - $52.92

Target Price

$58.89

Short %

6.42%

Short Ratio

4.11

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
GH vs. VOO GH vs. MRNA GH vs. EXAS
Popular comparisons:

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Guardant Health, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%80.00%100.00%120.00%December2025FebruaryMarchAprilMay
29.44%
95.20%
GH (Guardant Health, Inc.)
Benchmark (^GSPC)

Returns By Period

Guardant Health, Inc. (GH) returned 36.43% year-to-date (YTD) and 123.61% over the past 12 months.


GH

YTD

36.43%

1M

4.70%

6M

45.79%

1Y

123.61%

5Y*

-13.95%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of GH, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202553.78%-9.43%0.12%10.87%-11.75%36.43%
2024-18.93%-13.36%8.58%-12.75%50.56%6.57%21.64%-27.18%-10.32%-4.62%62.75%-14.21%12.94%
202315.55%-1.72%-24.12%-3.75%29.96%22.10%8.99%0.15%-24.16%-12.69%-2.74%7.47%-0.55%
2022-30.46%-4.72%-0.05%-6.85%-33.58%-1.56%24.37%-0.22%7.53%-8.04%5.74%-48.03%-72.81%
202120.65%-5.35%3.72%4.15%-21.93%0.06%-11.59%15.91%-1.78%-6.58%-9.99%-4.85%-22.39%
2020-2.69%14.36%-19.96%10.57%17.45%-10.24%4.99%12.12%17.05%-4.58%13.56%6.41%64.93%
20197.32%65.20%15.10%-14.59%17.36%12.29%8.87%-6.87%-27.08%8.88%11.76%0.61%107.87%
20183.98%6.72%5.21%16.74%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 90, GH is among the top 10% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GH is 9090
Overall Rank
The Sharpe Ratio Rank of GH is 9494
Sharpe Ratio Rank
The Sortino Ratio Rank of GH is 9292
Sortino Ratio Rank
The Omega Ratio Rank of GH is 8787
Omega Ratio Rank
The Calmar Ratio Rank of GH is 8888
Calmar Ratio Rank
The Martin Ratio Rank of GH is 8989
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Guardant Health, Inc. (GH) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current Guardant Health, Inc. Sharpe ratio is 1.79. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Guardant Health, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00December2025FebruaryMarchAprilMay
1.79
0.48
GH (Guardant Health, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Guardant Health, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-76.73%
-7.82%
GH (Guardant Health, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Guardant Health, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Guardant Health, Inc. was 91.03%, occurring on Apr 19, 2024. The portfolio has not yet recovered.

The current Guardant Health, Inc. drawdown is 76.73%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.03%Feb 16, 2021800Apr 19, 2024
-46.47%Aug 9, 2019151Mar 16, 2020135Sep 25, 2020286
-34.74%Mar 18, 201925Apr 22, 201975Aug 7, 2019100
-29.44%Dec 7, 201812Dec 24, 201835Feb 14, 201947
-19.99%Oct 18, 20188Oct 29, 201824Dec 3, 201832

Volatility

Volatility Chart

The current Guardant Health, Inc. volatility is 21.27%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%December2025FebruaryMarchAprilMay
21.27%
11.21%
GH (Guardant Health, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Guardant Health, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Guardant Health, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 42.4% positive surprise.


-1.40-1.20-1.00-0.80-0.60-0.40-0.2020212022202320242025
-0.49
-0.85
Actual
Estimate

Valuation

The Valuation section provides an overview of how Guardant Health, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for GH relative to other companies in the Diagnostics & Research industry. Currently, GH has a P/S ratio of 7.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for GH in comparison with other companies in the Diagnostics & Research industry. Currently, GH has a P/B value of 55.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items